Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pharvaris N.V. (NQ: PHVS ) 22.61 +0.29 (+1.30%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Pharvaris N.V. < Previous 1 2 3 4 5 Next > Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting October 24, 2024 Data from randomized clinical studies and long-term extension studies support deucrictibant’s potential best-in-class profile, detailing its injectable-like efficacy, placebo-like tolerability, and... From Pharvaris N.V. Via GlobeNewswire Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings October 16, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Host Virtual Investor Event on October 23, 2024 October 15, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop October 03, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Provides Business Update and Expands Development Program for Deucrictibant September 05, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 September 05, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Presents Data at the Bradykinin Symposium 2024 September 05, 2024 From Pharvaris N.V. Via GlobeNewswire Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium August 28, 2024 From Pharvaris N.V. Via GlobeNewswire PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024 August 14, 2024 PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update August 14, 2024 From Pharvaris N.V. Via GlobeNewswire Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. Via Investor's Business Daily Pharvaris Announces Annual Meeting of Shareholders June 11, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses June 04, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses May 13, 2024 From Pharvaris N.V. Via GlobeNewswire PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 May 08, 2024 PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Pharvaris N.V. Via GlobeNewswire PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 April 10, 2024 PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 10, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer April 10, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference April 04, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses March 18, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses March 06, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 March 05, 2024 From Pharvaris N.V. Via GlobeNewswire Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting February 22, 2024 Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks From Pharvaris N.V. Via GlobeNewswire Pharvaris Announces Extraordinary Meeting of Shareholders February 16, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris to Present at the WSAAI Annual Meeting 2024 January 26, 2024 From Pharvaris N.V. Via GlobeNewswire Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision January 22, 2024 The company is working on a treatment for swelling attacks associated with a genetic disease. Via Investor's Business Daily Exposures Product Safety FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps January 22, 2024 Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment. Via Benzinga Exposures Product Safety Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks January 22, 2024 From Pharvaris N.V. Via GlobeNewswire Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities January 05, 2024 From Pharvaris N.V. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
